Mid-Cap CytomX Therapeutics' Colorectal Cancer Data Fuels Stock Rally

The latest data revealed on Monday confirmed response rates in expansion cohorts of 32% at a 10 mg/kg Q3W dose and 20% at an 8.6 mg/kg Q3W dose, with an estimated progression-free survival of 7.1 months at the higher dose.